Lithium treatment reduces the renal kalHkrein excretion rate. Lithium salts are widely used agents for the prophylactic treatment of affective disorders. Lithium salts may be associated with distal nephron dysfunction. Kallikrein is a protease which is generated by the distal nephron. We used an amidolytic assay of chromatographically purified enzyme to determine the urinary excretion rate of active kallikrein in relation to lithium treatment. All plasma lithium concentrations were within the therapeutic range (0.4 to 0.9 mmol/liter). In 15 patients the urinary excretion rate of active kallikrein was 267.4 ± 65.6 mU/24 hrs before lithium treatment, and fell to 117.8 ± 39.6 mU/24 hrs (P < 0.05) on day 14 of lithium treatment. This reduction was associated with a decrease of immunoreactive kallikrein in the same urines by 66%. In another 15 patients who had undergone lithium therapy for an average period of 5.6 years, the urinary excretion rate of active kallikrein was 86.1 ± 14.5 mU/24 hrs, while 21 age-matched healthy controls had an excretion rate of 364.1 ± 58.4 m U/24 hrs (P < 0.05). Measurements of immunoreactive kallikrein in the same urine sampIes demonstrated a reduction of kallikrein after long-term lithium treatment by 78%. These observations could not be attributed to changes in creatinine cIearance, renal sodium or potassium excretion rates or plasma concentrations of aldosterone and vasopressin. Addition of lithium to the urine in vitro had no demonstrable effect on kallikrein measurement by amidolytic assay. We concIude that lithium in therapeutic plasma concentrations may directly suppress the secretion of kallikrein by renal connecting tubule cells.
Lithium treatment reduces the renal kalHkrein excretion rate. Lithium salts are widely used agents for the prophylactic treatment of affective disorders. Lithium salts may be associated with distal nephron dysfunction. Kallikrein is a protease which is generated by the distal nephron. We used an amidolytic assay of chromatographically purified enzyme to determine the urinary excretion rate of active kallikrein in relation to lithium treatment. All plasma lithium concentrations were within the therapeutic range (0.4 to 0.9 mmol/liter). In 15 patients the urinary excretion rate of active kallikrein was 267.4 ± 65.6 mU/24 hrs before lithium treatment, and fell to 117.8 ± 39.6 mU/24 hrs (P < 0.05) on day 14 of lithium treatment. This reduction was associated with a decrease of immunoreactive kallikrein in the same urines by 66%. In another 15 patients who had undergone lithium therapy for an average period of 5.6 years, the urinary excretion rate of active kallikrein was 86.1 ± 14.5 mU/24 hrs, while 21 age-matched healthy controls had an excretion rate of 364.1 ± 58.4 m U/24 hrs (P < 0.05). Measurements of immunoreactive kallikrein in the same urine sampIes demonstrated a reduction of kallikrein after long-term lithium treatment by 78%. These observations could not be attributed to changes in creatinine cIearance, renal sodium or potassium excretion rates or plasma concentrations of aldosterone and vasopressin. Addition of lithium to the urine in vitro had no demonstrable effect on kallikrein measurement by amidolytic assay. We concIude that lithium in therapeutic plasma concentrations may directly suppress the secretion of kallikrein by renal connecting tubule cells.
The effectiveness of lithium as a prophylactic treatment of affective disorders is well established [1] . The large number of patients affiicted and the necessity to prescribe lithium treatment over prolonged periods-often involving many years [1, 2]-has raised concern about potential side-effects of this medication [3] . In the kidney adverse effects may occur at therapeutic plasma levels of lithium. They inelude nephrogenic diabetes insipidus [4] , defective distal tubular acidification [5] and others [3] . In addition, renal morphological changes have been observed in distal tubular, connecting tubular and collecting duct epithelia [6] [7] [8] [9] [10] [11] [12] . Taken together, these observations indicate a preferential involvement of the distal nephron in those adverse effects.
Kallikrein is an enzyme which may generate kinins [13] . In the kidney kallikrein is produced and released by connecting tubular epithelial cells of the distal nephron [13] [14] [15] [16] . We were intrigued by the elose spatial relationship between the site of Received for publication October 12, 1989 and in revised form February 9, 1990 Accepted for publication February 13, 1990 © 1990 by the International Society of Nephrology kallikrein release and the localization of functional and morphological changes observed after lithium in the kidney. We asked the question whether lithium treatment might also affect renal kallikrein. A plasma lithium concentration of 0.4 to 0.9 mm01l1iter is considered therapeutic at our institution; patients included in our study did not exceed this range of concentrations. In all instances lithium therapy had been recommended by the psychiatrists in charge of the patient. All patients had given prior consent to the procedures of the study.
Methods

Patients
Protocol of evaluation
When a patient was entered into the study, we obtained a his tory , a complete physical examination and a standardized blood sampie at rest. We documented the present symptoms, the indications for lithium treatment, the current medication and any historical evidence of recent dehydration. In the physical examination, we searched for signs of dehydration or plasma volume contraction. All blood sampIes were drawn at about 3 p.m.; patients were not fasting. After placement of a short indwelling catheter into a forearm vein, the patient rested supine for 40 minutes. A 14 ce blood sampIe was drawn, immediately partitioned into the appropriate iced tubes, placed on ice and rapidly centrifuged at 3°C, at 4,800 x g for 10 minutes. The following parameters were measured: electrolytes ineluding lithium, magnesium and calcium; creatinine, urea and urate; total protein and albumin; osmolality; plasma renin activity (PRA); aldosterone and antidiuretic hormone (ADH).
Urine sampies . All measurements were based on the consecutive collection of two 24-hour urine specimens. These specimens were pooled and submitted for measurements thereafter. Specific precautions were taken to ensure completeness of colJection. While the collection was in progress, urine sampies were kept in a refrigerator at 3°C. The folJowing parameters were determined: urinary volume; osmolality; creatinine c1ear-ance; electrolytes including magnesium and phosphate; the kallikrein excretion rate was determined by amidolytic assay and by radioimmunoassay (RIA).
Laboratory procedures
Osmolality (normal range: 280 to 300 mOsm/kg H 2 0) was measured by freezing point depression on an Osmomat 030 (Gonotec GmbH, Berlin, FRG) as described [18] ; sodium, potassium and lithium concentrations (recommended range of lithium: 0.4 to 0.9 mmol/liter) were determined by flame photometry (Beckman Instruments, Munich, FRG); creatinine, urea (normal range: 15 to 45 mg/dl) , urate (normal range: 2.0 to 7.0 mg/dl), calcium, albumin and total protein concentrations by autoanalyzer (Technicon, Dublin, Ireland, UK); magnesium concentration by atomic absorption spectrophotometry (Perkin Eimer, model 290, Überlingen, FRG). The plasma aldosterone concentration (normal range: 2.0 to 10.0 ng/dl) was determined by RIA [19] ; PRA by the method of Haber et al with minor modifications (range of normal results at rest: 0.3 to 2.0 ng AI/mi x hr) [20] ; ADH by RIA as described [21] (the mean plasma ADH concentration in 20 adult volunteers by this assay was 2.9 ± 1.0 pg/ml).
Specijic measurements
The amidolytic assay of kallikrein was based on previously described methods [22] [23] [24] [25] [26] [27] . In short, aliquots of thawed urine were dialyzed against distilled water for 24 hours. This was folJowed by dialysis against a phosphate-buffered (10 mM, pH 7.0) KCI solution for an additional 24 hours. Dialyzed urine sampies were passed through columns containing DEAE-SEPHADEX A-50 (Pharmacia Fine Chemicals, Freiburg, FRG), 4 cc per column. Kallikrein was eluted with phosphatebuffered KCI solution (700 mM of KCl) after rinsing with 200 mM KCI. No correction was made for losses. Amidolytic activity was determined by incubating 400 J.d of eluate with 0.15 mM D-VAL-LEU-ARG-PARANITROANILIDE (S 2266, Kabi Diagnostica GmbH, Munich, FRG) and 5oo,uI ofTRIS-HCI (pH 8.2; 0.2 mol/liter). Incubation was maintained for 30 minutes at 37°C, after which the reaction was stopped by addition of loo,ul of 50% acetic acid. The enzymatic c1eavage of S 2266, yielding p-nitroaniline, attributable to the enzymatic activity of kallikrein was measured photometrically (Perkin Eimer 550 A, Oak Brook, Illinois, USA) at 405 nm against a blank. Results of measurements are reported in units (U) ; one unit is the amount of enzyme capable of c1eaving one ,umol of S 2266 per minute at 37°C. The range of normal values for urinary kallikrein determined by this assay is reported by our laboratory as 310 to 420 mU/24 hrs. The following parameters were also measured, but remained normal and unaltered: a) plasma concentrations of sodium, potassium, calcium, phosphate, magnesium, albumin and total protein; b) urinary excretion rates of phosphate and osmoles.
Radioimmunoassay 0/ kallikrein
The method used has been described in detail [28] . In the assay an antibody against kallikrein raised in rabbits was used. The lower limit of detection of kallikrein by this assay is 0.5 ,uglliter. The range of normal values of kallikrein measured by this assay is reported by our laboratory as 60 to 100 ,ug/24 hrs.
For measurements of kallikrein by RIA, which will be reported in the subsequent section on resuIts, we routinely employed the same pretreatment of urine sampies as described above for amidolytic assay. However, in a sub set of 12, randomIy-selected urine specimens, we also compared results obtained by amidolytic assay as described above with those by radioimmunoassay without urinary pretreatment. A significant correlation of both measurements was found (N = 12; r = 0.89; P < O.OOO}).
Statistics
Results of measurements are reported as mean values ± SEM. The Wilcoxon signed rank test was used for comparison between groups of data.
Results
General observations in short-term lithium treatment
In all 15 patients (women: 9, men: 6; mean age 39 years, range 18 to 67) a diagnosis ofDSM-III affective disorder [17] had been established. During the first 14 days of treatment plasma concentrations of lithium were within the therapeutic range «0.9 mM; 94.4 ± 3.7 mm Hg), but the change was not significant (P < 0.09). Table 1 shows parameters which document hydration, extracellular fluid volume status, creatinine clearance and potential imbalances of renal electrolyte handling at the time of kallikrein measurement. Osmolar clearance was 2.2 ± 0.08 mlfmin at baseline and 2.2 ± 0.09 on day 14 of lithium therapy (P = NS); free water clearance at baseline was -0.86 ± 0.07 mlfmin, and on day 14 of lithium therapy was -0.97 ± 0.08 (P = NS). All of these data failed to demonstrate any abnormalities or significant changes after the beginning of lithium treatment.
General observations in long-term lithium treatment
The 15 patients (women: 6, men: 9; mean age 39 years, range 14 to 66) underwent an abbreviated evaluation primarily to measure urinary kallikrein excretion. At the time of our study, the average duration of lithium treatment had been 5.6 years. Physical examination demonstrated normal hydration. The 24-hour urinary volume was 2.1 ± 0.3 liter. The serum lithium concentration was 0.8 ± 0.08 mM/liter. Serum electrolytes and concentrations of urea and urate were all within normal limits; the plasma creatinine concentration was 0.99 ± 0.1 mg/dl, which was normal. Urinary protein excretion rate was less than 200 mg/24 hrs in all.
Kallikrein in 24-hour urine sampIes
Short-term lithium treatment was associated with a significant reduction of the excretion rate of active kallikrein (amido- lytic assay) by 56% (Fig. 1) . This reduction was apparent as early as 72 hours after the beginning of lithium treatment. Thus, four randomly selected patients who collected urine sampies at 72 hours after the beginning of lithium treatment had a reduced excretion of active kallikrein of 117.4 ± 77.8 mU/24 hrs (data not shown in Fig. 1 ). Figure 1 also demonstrates comparable findings in 15 patients who had undergone long-term lithium treatment over several years. Results of measurements of immunoreactive kallikrein are shown in Figure 2 . The measurements were performed on eluates from the same 24-hour urine sam pies that had also been subjected to amidolytic assay yielding the results reported in Figure 1 . The set of observations of active kallikrein (amidolytic assay, Fig. 1 ) closely resembled the set of observations of immunoreactive kallikrein (Fig. 2) . When the results of both methods of measurement were analyzed by regression analysis they were significantly correlated (N = 66; r = 0.62; P < 0.00001).
lnfluence 01 lithium on amidolytic assay Eight control urine sampies were selected at random and divided into two aliquots of equal volume. Lithium carbonate was added to each second aliquot yielding a final concentration of 5 mM/liter of lithium. Kallikrein activity was determined subsequently in all 16 sampies by a blinded observer. Kallikrein was 412 ± 9.1 mU in the eight sampies without lithium addition and 414 ± 10.4 (P = NS) after pretreatment by lithium. Thus, there was no difference between amidolytic measurements in the presence or absence of lithium in urine sampies.
Discussion
The urinary kallikrein excretion rate was found to be significantly reduced in association with lithium treatment. This finding was demonstrated by two different methods of assay for urinary kallikrein: the amidolytic assay of active kallikrein and the radioimmunoassay. No attempts were made to measure inactive kallikrein by amidolytic assay after its activation. We were able to exclude an interference between lithium and the amidolytic assay. Reduced kallikrein excretion was consistently present in different stages of lithium therapy. It could be documented as early as 72 hrs after the beginning of lithium therapy, as weH as after 14 days and several years of such therapy. Reduced kallikrein excretion occurred in patients that had plasma lithium concentrations within the therapeutic range. There was no evidence of renal insufficiency [29, 30] in these patients. No changes of ADH [31] , aldosterone [32] , or potassium and sodium output [33] [34] were found that might have contributed to the observed reduction of kallikrein excretion. Therefore, we propose that lithium per se causes reduced renal kallikrein excretion at low plasma concentrations. To our knowledge this has not been reported before. However, as documented in arecent preliminary report from our laboratory, it was possible to reproduce the same finding in experimental animals [35] . The latter observations indicated a reduced urinary excretion rate of kallikrein along with a reduced renal cortical content of kallikrein during lithium treatment in the rat.
Several renal side-effects of lithium have been reported. They are: nephrogenic diabetes insipidus [4, 9, 36] , reduced glomerular filtration rate [37] [38] [39] , hypercalcemia [40] and increased excretion of sodium, potassium, calcium and phosphate by the kidney [41] [42] [43] . None ofthese adverse effects were noted in the patients of our study. Distal tubular acidification, which may also be impaired [5, 44, 45] , was not tested. Thus, our findings do not clarify the relationship between the observed reduction of kallikrein and the development of adverse effects of lithium in the kidney. However, we were intrigued by findings in a single patient with lithium intoxication-not mentioned in the above-who had a plasma lithium concentration of 2.8 mM/liter, urinary kallikrein concentration too low to be detectable by our assay, and nonoliguric deterioration of renal function.
In future studies, the establishment of a relationship between the plasma concentration of lithium and any renal side-effects of this medication might be attempted. Conceivably, there could be an order of increasing severity in renal side-effects, in which reduced excretion of kallikrein might be an early event. In addition, in such future studies, it mayaiso be worthwhile to test the effect of lithium-and thereby of reduced kallikrein-on renal perfusion. If a relationship of this kind existed, it might contribute to the understanding of renal lithium toxicity.
